Generic Drugs’ 10-Year Savings To U.S. Health System Top $1 Tril. For First Time, GPhA Finds
This article was originally published in The Pink Sheet Daily
Generic Pharmaceutical Association, with research from IMS Health, says the savings to the U.S. health care system from using generic drugs were $1.07 trillion over the past 10 years, a figure the group believes should be taken into consideration when looking for solutions to the general fiscal crisis facing the U.S. The association is going to focus on improving generic utilization on state and local level.
You may also be interested in...
FDA’s Denise Esposito says that in many cases the agency will require biosimilar sponsors to conduct head-to-head comparison studies with the reference product.
The new molecular entity and novel biologic class of 2011 isn’t just the largest since 2004 – CDER also posted near-perfect on-time review performance while maintaining healthy rates of first-cycle approvals and a low 15 month average time to approval, thanks to a high level of innovation in the novel product candidates.
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.